Key result
Pretreatment with the PPAR-alpha agonist WY-14643 significantly reduced myocardial infarct size from 34% to 18% compared to controls in rat hearts exposed to ischemia/reperfusion.
Why the study?
Does pretreatment with PPAR-alpha agonist WY-14643 reduce ischemia/reperfusion injury in a rat heart model?
Does pretreatment with PPAR-alpha agonist WY-14643 reduce ischemia/reperfusion injury in a rat heart model?
PPAR-alpha activation prior to ischemia/reperfusion in a rat model reduces myocardial injury, potentially via metabolic shifts toward fatty acid oxidation and activation of the PI3K/Akt/eNOS pathway.
Answers are grounded in this paper and cite their sources.
May support metabolic cardioprotection strategies; leaves open translation from rat models to clinical ischemia/reperfusion injury.
UNLABELLED: Genes encoding enzymes involved in fatty acids (FA) and glucose oxidation are transcriptionally regulated by peroxisome proliferator-activated receptors (PPAR), members of the nuclear receptor superfamily. Under conditions associated with O(2) deficiency, PPAR-alpha modulates substrate switch (between FA and glucose) aimed at the adequate energy production to maintain basic cardiac function. Both, positive and negative effects of PPAR-alpha activation on myocardial ischemia/reperfusion (I/R) injury have been reported. Moreover, the role of PPAR-mediated metabolic shifts in cardioprotective mechanisms of preconditioning (PC) is relatively less investigated. We explored the effects of PPAR-alpha upregulation mimicking a delayed "second window" of PC on I/R injury in the rat heart and potential downstream mechanisms involved. Pretreatment of rats with PPAR-alpha agonist WY-14643 (WY, 1 mg/kg, i.p.) 24 h prior to I/R reduced post-ischemic stunning, arrhythmias and the extent of lethal injury (infarct size) and apoptosis (caspase-3 expression) in isolated hearts exposed to 30-min global ischemia and 2-h reperfusion. Protection was associated with remarkably increased expression of PPAR-alpha target genes promoting FA utilization (medium-chain acyl-CoA dehydrogenase, pyruvate dehydrogenase kinase-4 and carnitine palmitoyltransferase I) and reduced expression of glucose transporter GLUT-4 responsible for glucose transport and metabolism. In addition, enhanced Akt phosphorylation and protein levels of eNOS, in conjunction with blunting of cardioprotection by NOS inhibitor L-NAME, were observed in the WY-treated hearts. CONCLUSIONS: upregulation of PPAR-alpha target metabolic genes involved in FA oxidation may underlie a delayed phase PC-like protection in the rat heart. Potential non-genomic effects of PPAR-alpha-mediated cardioprotection may involve activation of prosurvival PI3K/Akt pathway and its downstream targets such as eNOS and subsequently reduced apoptosis.
No takes yet. Share an insight, caveat, or question.
Ravíngerová et al. (2013) studied Myocardial ischemia/reperfusion injury (n=62). WY-14643 vs. DMSO solvent (untreated controls) was evaluated on Size of myocardial infarction (% of area at risk) (p=<0.05). Pretreatment with the PPAR-alpha agonist WY-14643 significantly reduced myocardial infarct size from 34% to 18% compared to controls in rat hearts exposed to ischemia/reperfusion.
Synapse has enriched 10 related papers. Consider them for comparative context: